Latest News about AZN
Recent news which mentions AZN
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
From Motley Fool
From Benzinga
AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study
January 19, 2024
From Benzinga
Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold
January 15, 2024
From InvestorPlace
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
From Benzinga
Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense
January 11, 2024
From Benzinga
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry
January 09, 2024
From Benzinga
4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
January 06, 2024
From Motley Fool
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
From Benzinga
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
January 05, 2024
From Benzinga
7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024
January 03, 2024
Tags
HES
NASDAQ:NVDA,NASDAQ:DOX,NYSE:STNG,NYSE:GOLD,NYSE:VALE,NASDAQ:AZN,NYSE:CVX,NYSE:LMT,NYSE:HES
STNG
From InvestorPlace
From InvestorPlace
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
January 02, 2024
From Benzinga
From Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
From Benzinga
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
December 28, 2023
From Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
From InvestorPlace
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
From Benzinga
Investor Sentiment Improves; Dow Jumps Over 150 Points
December 27, 2023
From Benzinga
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
December 26, 2023
From Benzinga
Crude Oil Rises Over 3%; US Home Prices Increase In October
December 26, 2023
From Benzinga
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry
December 26, 2023
From Benzinga
From Benzinga
US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs
December 26, 2023
From Benzinga
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
December 26, 2023
From Benzinga
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
December 22, 2023
From Benzinga
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
December 22, 2023
From Benzinga
These 3 Big Pharma Stocks Are Making Big Plays With AI
December 22, 2023
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.